人端粒酶逆转录酶在肿瘤免疫治疗中的应用  

Applications of human telomerase reverse transcriptase in tumor immunotherapy

作　　者：仇全[1] 李颖[1] 钱关祥[1] 

机构地区：[1]上海第二医科大学基础医学院生化与分子生物学教研室,上海,200025

出　　处：《上海第二医科大学学报》2004年第3期225-227,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：寻找有效的抗原表位是近期肿瘤免疫治疗的热点,人端粒酶逆转录酶(hTERT)的免疫学特性使其成为肿瘤免疫治疗中一个吸引人的目标。从人和鼠系统获得的数据证实,细胞毒淋巴细胞(CTL)能识别hTERT特异的肽并杀死多种组织类型hTERT表达的肿瘤细胞。由于hTERT在人肿瘤组织中的广泛表达,在极少正常组织的低水平表达,临床试验已开始检验将hTERT作为肿瘤免疫治疗目标的可行程度。近期树突状细胞(DC)转运系统及其相关技术的发展和成熟提供了一个快速有效筛选抗原肽的方法。The immunological properties of the telomerase reverse transcriptase human telomerase reverse trans-criptase(hTERT) suggest that the enzyme is an attractive target for novel immunotherapy against cancer. Data from both human and murine systems demonstrate that cytotoxic T-lympho- cytes (CTL) can recognize peptides derived from hTERT and kill hTERT-positive tumor cells of multiple histologies. Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun to test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer. Recently, the universal application of the DC delivery system and associated methods have offered us a quick and efficient approach of screening peptides.

关 键 词：人端粒酶逆转录酶 端粒酶 树突状细胞 细胞毒淋巴细胞 肿瘤细胞 免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]